During the past few years the metabolism of vitamin D has This investigation confirms the high level of biologic activity and the similarity of the effects of small doses of 1,25-dihydroxyvitamin D, (1,,-D,) and of its analog la-hydroxyvitamin D , (la-OH-D,) on children with nutritional rickets, "pseudodeficiency" rickets (PDR), hereditary hypophosphatemia, chronic idiopathic hypoparathyroidism, and chronic renal failure. It also shows that cystinotic patients may develop, at the end stage of the disease, a certain degree of resistance to 1,25-(OH),D,. The comparison of the therapeutic effects of long term oral administration of 1,25-(OH),-D, or la-OH-D, to two D-deficient children and two sibs with PDR demonstrates differences in sensitivity. In the patients with nutritional rickets, 0.5 pg/24 hr of either drug corrects the biochemical abnormalities, initiates healing of skeletal lesions in 28 days, and cures the metaphyseal lesions in 60 days of therapy. In contrast, it appears that doses of either drug that are curative in D deficiency rickets are only partly active in PDR. These observations indicate that the hypothesis of a deficit in 25-hydroxycholecalciferol la-hydroxylase in patients with PDR must await for confirmation more direct evidences, and that such a deficit, even if proven, may not account for all of the biochemical and skeletal alterations seen in patients with this inherited disorder.
Speculation
The similarity of action of 1,25-(OH),-D, and la-OH-D, observed in the present study presents additional evidence that la-OH-D, can be considered a valuable substitute for the hormonal form of cholecalciferol, especially for the management of children with chronic renal failure, hypoparathyroidism, or pseudodeficiency rickets. In this latter disease, the active therapeutic doses of either drug appear to be greater than the amount required for the treatment of simple nutritional rickets. This observation indicates that investigations on the pathogenesis of pseudodeficiency rickets must be continued in order to confirm or invalidate the hypothesis suggested by us and others that this inherited disorder might be related to a deficit in 25-hydroxycholecalciferol la-hydroxylase.
undergone extensive invkstigations. Results obtained so far have led to the isolation and identification of several active metabolites. Their sites of synthesis and the role of several ionic and/or hormonal factors for the activation or the inhibition of these syntheses have been analyzed (3, 21, 23, 26, 31) . The transport, storage, inactivation of these metabolites, and mechanism of their intracellular transport and action are currently under study in several laboratories. Even though incomplete, these new concepts of vitamin D metabolism are of great theoretical value. Furthermore, they help to clarify our understanding of vitamin D resistance observed in such diseases as chronic renal failure, hepatocellular failure, hypoparathyroidism, or during anticonvulsant therapy. Moreover they indicate that the use of these metabolites, especially that of the hormonal form 1,25-(OH),-D, instead of cholecalciferol itself, might provide a more specific treatment for some pathologic states. The chemical synthesis of 1,25-(OH),-D, is difficult and sufficient quantities for long term clinical trials are not easily available. Recently an analog of this active vitamin D derivative has been discovered: la-OH-D, (22) . Preparation of this compound is less difficult and less expensive (6, 18, 22) . The present investigation was undertaken in order to analyze the comparative biologic effects of 1.25-(OH),-D, and la-OH-D, in children with different types of D resistance, and to determine whether la-OH-D, could be a valuable substitute for 1,25-(OH),-D, in pediatric pharmacology.
Preliminary results obtained during this investigation established that children with P D R were sensitive to quite small doses of 1,25-(OH),-D,. These observations led us to suggest that this inherited disorder might be caused by a deficit in 25-hydroxycholecalciferol la-hydroxylase (4); a hypothesis also suggested by Fraser et al. (14) , and more recently by Prader (29) , Fanconi (l3), and Scriver et a/. (32) . According to this hypothesis the biochemical and skeletal lesions in PDR, just as they are in simple D deficiency rickets, may be related to a deficit in 1,25-(OH),-D,. Hence, one would expect children with P D R and patients with D deficiency rickets to respond similarly to 1,25-(OH),-D, or la-OH-D, therapy. In an attempt to test the validity of this assumption our study was completed by a cornparisin of the therapeutic effects of small daily oral doses of 1,25-(OH),-D, or deficiency rickets, 4 patients with pseudodeficiency D-resistant For 0" of the sibs with PDR the effects of la-OH-D, therapy rickets (PDR) as described by Prader, Illig, and Heier]i (30), 2 with were evaluated at two dose levels, i.e., 0.5 ~g / 2 4 hr for 25 days hereditary ~y p o p~o s p~a t e m i c ~-~~~i~t~~~ rickets (VDRR), 1 ado. then I hg/24 hr for 20 days. For this patient balance studies of lescent with late acquired ~-~~~i~~~~~ as described by stable calcium and phosphorus were performed during 14 5-day M~c~~~~ (25) , and who had been in spontaneous recovery for 18 periods. Carmine was used as a fecal marker. The patients with months, 1 patient with chronic idiopathic hypoparathyroidism, 4 D-deficiency rickets and the children with PDR had radiologic children with terminal stage chronic renal failure, and 2 children examinations of the wrist and knee bones at the initiation and at with cystinosis. In these different diagnostic groups the effects of the end of 1,25-(0H),-D3 la-OH-D3 short term administration of 1 , 2 5 -( 0~) , -~, were with During the short term and the long term studies the following some patients whereas I~-O H -D , was given to the others, ~h~ two biochemical data were collected: serum calcium, phosphorus, with cystinosis had severe impairment of their glomerular creatinine, citrate, alkaline phosphatase; urine calcium, phosfunctions, i.e,, creatinine clearances, were, respectively, 6 and 30 phorus creatinine, and cyclic AMP; endogenous creatinine clearml/min/1.73 m2; both received 1 , 2 5 -( 0~) , -~, , ~h~ effects of "=, tubular reabsorption of phosphorus (TRP), and phosphorus I ,~~-( o H ) , -D , and of la-0H-D, were analyzed in the same maximum tubular reabsorption rate per 100 ml glomerular patient with chronic idiopathic hypoparathyroidism, All children filtration rate (Tm/GFR) calculated according to the nomogram with VDRR or with PDR, the adolescent with late acquired of Bijvoet et al. (7) . The laboratory techniques used were the D-resistant rickets, and the patient with chronic idiopathic hypo-following: phosphorus, Fiske and SubbaRow (~u t o~n a l y z e r ) : parathyroidism had been previously treated with D or creatinine (AutoAnalyzer); calcium, automated complexometric 2 5 -0~-~, .
~h~~~~~ had been stopped for 2 months to 16 months titration (Marius calcium titrator, Amsterdam, Netherlands); when the present study was started. N~~~ of the other subjects had alkaline phosphatase, Bodansky method; citrate, an enzymatic received any vitamin D.
technique ( Holick and H. F. DeLuca. The drugs were administered orally as I ,~~-( o H ) , -D , had no effect on a n y of *he biochemical paramepropylene glycol solutions. Before their utilization all batches of ters studied in the two children with cystinosis, F~~ all other 1,25-(OH)z-D, and of Ia-OH-D, were tested for their biologic patients oral administration of 2 hg/24 hr for 5 days of the active activity. Doses used were 2 ,.tg/24 hr for 5 days for 1,25-(OH)z-D, metabolite of vitamin D promoted a clear-cut rise in serum and 1 ,.tg/24 hr for 5 days for 1 a-OH-D3 in all cases studied, ex-calcium concentrations (~i~, 1 ), ~n increase in serum phosphorus cept for the patient with chronic idiopathic hypoparathyroidism concentrations was observed in the child with D deficiency rickets, who was given 2 ,.tg/24 hr for 5 days of la-OH-D3 then, after an three patients with pseudodeficiency rickets, and the child with interval of 7 days, 2 ,.tg/24 hr for 5 days of 1,25-(OH),-D, VDRR (Fig. 2 ). In this last patient a transient rise in T R P , i.e., 61% during therapy vs 36% during the control period, occurred. Serum phosphorus decreased slightly then increased sharply in the two children with severe chronic renal failure. In contrast, in the adolescent with chronic idiopathic hypoparathyroidism 1,25-(OH),-D, administration promoted a fall in serum phosphorus concentration; this effect persisted I week after cessation of therapy. N o changes of endogenous creatinine clearance were observed during this investigation. The effects of 1,25-(OH),-D, on serum citrate, as on the other parameters studied, were variable from case to case.
Chronic idiopathic D-clef iciency

BIOLOGIC EFFECTS O F SHORT TERM ADMINISTRATION
O F 10-OH-D, Figure 3 illustrates the variations in serum calcium concentrations. A rise was observed in all subjects studied, either during la-OH-D, administration or during the post-treatment period. The maximal variation from baseline level (+ 1.4 mg/ 100 ml) was found in a D-deficient, severely hypocalcemic child who had been given iv calcium gluconate infusion 12 hr before la-OH-D, therapy. Serum phosphorus concentration (Fig. 4) decreased in the patient with chronic idiopathic hypoparathyroidism; in all other subjects, except one child with chronic renal failure receiving anticonvulsant therapy, serum phosphorus concentration rose. An augmentation in serum citrate concentration was found in seven of eight subjects studied. A transient rise in T R P occurred during therapy in the child with V D R R . la-OH-D, did not modify endogenous creatine clearance and urinary excretion of calcium; the effects on serum alkaline phosphatase and urinary excretion of cyclic A M P were variable.
This study was carried out with two sibs with pseudodeficiency rickets and one child with D deficiency rickets. The patients with PDR were aged, respectively, 5 years and 7 years when the present investigation was started. They had both been under the medical survey of one of us (S.B.) for the past 5 years. During this period of time their requirements for 25-OH-D, had been found to be between 250 and 300 j~g/24 hr in order to obtain and maintain a normal growth, normalization of biochemical parameters, and complete healing of skeletal ricketic lesions. For these patients 25-OH-D, therapy had been stopped for 2 months when the biologic and therapeutic effects of 1,25-(OH),-D, were studied. Forty-five days after the end of the short term protocol they were given 1 pg/24 hr of 1,25-(OH),-D, for 28 days (Fig. 5) . When this treatment was started both children were in evident relapse as substantiated by low serum calcium and phosphorus concentrations (8.3 and 8.1 mg/ 100 ml for calcium and 2.9 and 3.3 mg/ 100 ml for phosphorus) and typical metaphyseal ricketic x-ray lesions. Treatment with 1,25-(OH),-D, promoted normali~ation of serum calcium and phosphorus concentrations. Serum calcium increased, respectively, to 9.8 and 9.9 mg/100 ml; serum phosphorus rose progressively and was found at 4.1 and 6.2 mg/100 ml ( lesions. She was treated during 2 months with a daily oral dose of 0.5 pg biosynthetic 1,25-(OH)z-D3. She received during this period a total dose of 30 pg. A rapid normalization of her serum calcium phosphorus alkaline phosphatase and of her P T m / G F R was obtained (Fig. 6) . This treatment promoted a complete healing of her x-ray metaphyseal lesions. N o biochemical or radiologic evidence of a relapse was observed 2 months after cessation of 1,25-(OH),-D, administration.
The effects of long term administration of la-OH-D, were investigated with two patients: a 16-month-old child with D deficiency rickets and one patient with pseudodeficiency rickets who had been treated previously with 1.25-(OH),-D, For the child with D deficiency, treatment was restarted with la-OH-D, 5 days after the end of the short term protocol. At that time, the laboratory data for this patient were as follows: serum calcium 9. I mg/100 ml: serum phosphorus 4.1 mg/100 ml; serum alkaline phosphatase 29 Bodansky units (Bod. u) (Fig. 7) . Serum citrate was normal at 2.3 mg/ 100 ml. Urinary cyclic A M P to creatinine ratio was elevated to 25; phosphorus T m / G F R was 3.44. On treatment with 0.5 pg/24 hr for 28 days serum calcium and citrate remained in the normal range, serum phosphorus concentration increased progressively and reached 6.1 mg/ 100 on the 28th day, and serum alkaline phosphatase activity became normal. T m / G F R reached 5.19, whereas urinary cyclic A M P to creatinine ratio fell to 7.2 on the 21st day. Comparison of radiograms obtained at the start and at the end of la-OH-D, therapy demonstrated initiation of healing of the bone lesions. One week after cessation of treatment serum calcium had decreased from 9.7 to 8.9 mg/100 ml; serum phosphorus was still at high normal concentration (5.8 m g j 100 ml).
Two months after the end of long term administration of 1,25-(OH),-D, the biologic and therapeutic effects of la-OH-D, were investigated with the 7 years old sib with pseudodeficiency rickets. At that time as can be seen in Figure 8 this patient was in biochemical relapse: x-ray examination demonstrated the reappearance of skeletal ricketic lesions, and balance studies showed a negative calcium balance with a poorly positive phosphorus balance (Fig. 9) . The effects of la-OH-D, were studied at two dose levels: 0.5 pg/24 hr for 25 days, then 1 pg/24 hr for 20 days.
On long term treatment with 0.5 g/24 hr for 25 days (Fig. 8) , serum calcium concentration augmented progressively and reached 7.9 mg/100 ml. Serum phosphorus concentrations, after an initial rise to 4.2 mg/100 ml, fell and remained stabilized around 3.2 mg/100 ml, likewise serum citrate concentration increased from 2.2 mg to 3.0 mg/100 ml on the 5th day, then decreased to 1.4 mg/ 100 ml. The results obtained in the first period of the balance studies during long term treatment indicated a positive balance for calcium (+ 114 mg/24 hr) and for phosphorus (+253 mg/24 hr); during the subsequent periods calcium balances were at equilibrium and phosphorus balances were only slightly positive. When the daily oral dose of la-OH-D, was doubled, the calcium balance of this patient became positive again ( + I 12 mg/24 hr) and remained so throughout the study. A further elevation of serum calcium concentration occurred; serum calcium reached 8.6 mg/100 ml after 3 weeks of therapy. Serum alkaline phosphatase fell from 22.3 to 11.4 Bodansky units. In contrast, no significant changes in serum phosphorus concentration were observed. Net intestinal absorption of phosphorus increased, as
shown by a diminution of fecal phosphorus excretion (Fig. 9) .
NUTRITIONAL RICKETS AND VITAMIN D RESISTANCE
However, this improvement in intestinal absorption was followed, increased urinary output and a decreased tubular reabsorption of phosphorus. As a consequence the phosphorus balances became less and less positive during the last two periods' of la-OH-D, therapy. Five days after la-OH-D, treatment was stopped, serum calcium concentration fell to 7.5 mg/100 ml, and once again net intestinal calcium absorption decreased, leading to a negative calcium balance. For this patient, the radiologic examinations done at the end of la-OH-D, therapy at each dose level showed the persistance of ricketic lesions. When these x-rays were compared to the pretreatment radiographs, no healing nor aggravation could be detected.
PHOSPHORUS ma /day
DISCUSSION
This investigation confirms the high biologic activity of small doses of 1,25-(OH),-D, and of its analog la-OH-D, in children. The effects observed are: a constant rise in serum calcium concentration in all subjects studied except in cystinotic patients with severe glomerular function impairment; an increase in serum phosphorus and citrate concentration in patients with D deficiency rickets; a lack of normalization of the low serum phosphorus and T R P in hereditary hypophosphatemic D-resistant rickets; a rise in serum calcium with a fall in serum phosphorus in chronic idiopathic hypoparathyroidism. These data are in agreement with the effects reported on children (8, 12-14, 17, 20, 29, 32) and on adults (9-1 1, 20, 28 Fig. 5,-) .
The arrow ~ndicates the end of 1,25-dihydroxyvitamin D, treatment shown in Figure 5 . S, , , serum citrate concentrations; S,, and S, , : serum Ca and P concentrations, respectively; Alk. P'ase: serum aikaline phosphatase; Bod. u.: Bodansky units. (19) . However, in the comparison of long term administration of 1,25-(OH),-D, or la-OH-D, to D-deficient children and these two sibs with P D R differences in sensitivity are shown. In the two patients with nutritional rickets 0.5 j~g / 2 4 hr of either drug corrects the biochemical abnormalities, initiates healing of skeletal lesions in 28 days, and cures the metaphyseal lesions in 60 days of therapy. In contrast, for the children with PDR the minimal requirement for 1,25-(OH),-D, appears to be 1 &24 hr for 28 days and this total dose of 28 g g is not sufficient to achieve healing of bone lesions. Therapy with ICY-OH-D, first with 0.5 pg/24 hr for 25 days then with 1 pg/24 hr for 20 days, i.e., a total dose of 32.5 kg, promotes a rise in serum calcium concentration and net intestinal calcium balance, but does not increase serum phosphorus and has no effect on the skeletal alterations. We have shown in a preliminary report of another sibling with PDR that the requirements for 1,25-(OH),-D, or la-OH-D, of the affected children were also quite high, i.e., 2-4 pg/24 hr and 4-8 pg/24 hr, respectively, for each drug (5). Thus, it appears clearly that does of either 1,25-(OH),-D, or la-OH-D, that are curative in D deficiency rickets are only partly active in PDR. Scveral factors such as body mass, severity of secondary hyperparathyroidism, importance of skeletal lesions, or degree of calcium and/or phosphorus depletion may be of importance in this respect. Body mass was obviously different in our two groups of patients: the children with D deficiency rickets were, respectively, 16 and 26 months old, the patients with PDR were 5 and 7 years old. Yet, in the second sibling mentioned above ( 5 ) , the younger child, aged 8 years, with a body weight of 19 kg did not respond to 2 pg/24 hr of either 1,25-(OH),-D, or la-(OH)-D,, whereas her 12-year-old sister (body weight 29 kg) did respond to these doses. Secondary hyperparathyroidism has been reported in some patients with P D R (2) and in children with D deficiency ( I , 15, 24) . Measurements of serum immunoreactive parathyroid hormone were not done in the present investigation. Arnaud et al. (1, 2) reported, in their studies in P D R and in D deficiency, a direct correlation between hyperparathyroidism and the clinical severity of these diseases. The same conclusion can be drawn from the analysis of the results published by Fischer et al. (15) . For our patients the clinical symptoms, including x-ray bone lesions, were, in fact, more severe in the two children with D deficiency rickets. Finally, as for the possible role of a long standing calcium and/or phosphorus depletion in these children with PDR: they had been regularly treated with vitamin D then with 25-OH-D, for the past 5 years and their serum calcium and phosphorus concentrations were successfully maintained at normal levels as shown by regular biochemical analyses performed every 2-3 months. Thus, it appears that none of the possible explanations mentioned above help clarify this difference in sensitivity to 1,25-(OH),-D, and la-OH-D, observed in patients with P D R when compared with children with simple nutritional rickets.
These observations indicate that a deficit in 25-hydroxycholecalciferol la-hydroxylase alone may not account for all of the biochemical and skeletal alterations of pseudodefiency rickets. They also suggest that confirmation of this hypothesis for the pathogenesis of this inherited desorder must await more direct evidences. he fact that such a small dose, considered in the physiologic range, is active in P D R had previously led us and others to suggest that this inherited disorder may be caused by a deficit in 25-hydroxycholecalciferol I ahydroxylase. Our present investigation shows clearly that 0.5 pg/24 hr of either 1,25-(OH),-D, or la-OH-D, is a curative dose in D deficiency rickets but not in P D R . This difference in sensitivity does not seem to be related to differences in body mass, secondary hyperparathyroidism, severity of bone lesions or of calcium, and/or phosphorus depletion. It is concluded that confirmation of this hypothesis for the pathogenesis of P D R must await more direct evidences. 
Extract
The therapeutic response to chemically_synthesized la-hydroxycholecalciferol (la-OH-D,) was studied in three patients with autosomal recessive vitamin D dependency (ARVDD). The daily maintenance dose for vitamin D,, to prevent signs of vitamin D deficiency in these patients, was 40-54.5 fig/kg, or about 100 times normal (Table 1) . Withdrawal of maintenance therapy with vitamin D, resulted in the ultimate reappearance of the vitamin D depletion syndrome in patients I and 2 ( Figs. 1 and 2) . The third patient presented with the deficiency syndrome despite adequate vitamin D nutrition and was recognized to have ARVDD.
Treatment with la-OH-D, by mouth in all three patients at dose levels of 1-3 pg/24 hr (8@100 ng/kg) corrected hypocalcemia and suppressed parathyroid hormone-dependent renal loss of amino acids (Figs. 1,2, and 4) . Rickets healed in 7-9 weeks on la-OH-D, alone (Fig. 3 ) The therapeutic response was rapid. It was usually seen first in the rise of serum calcium (Figs. 5 and 6 ). Withdrawal of la-OH-D, was followed first by a fall of serum phosphorus, then by a fall in serum calcium; the latter occurred within about 2 weeks of withdrawal.
Because the synthesis of la-OH-D, is simpler than for la,25-dihydroxycholecalciferol and because the former is an effective therapeutic analog of vitamin D hormone, we believe these studies in ARVDD reveal la-OH-D, to be the agent of choice for treatment of this and analogous diseases.
Speculation
Vitamin D dependency or pseudodeficiency rickets is believed to be an inborn error of vitamin D hormone biosynthesis. The putative abnormal enzyme is 25-hydroxycholecalciferol 1-hydroxylase in the recessively inherited trait. Consequently, this experiment of nature offers a special opportunity to examine the requirement in human subjects, for la-hydroxyvitamin D, metabolites.
Patients with ARVDD (14, 18, 36) develop signs of severe postnatal vitamin D deficiency, despite a nutritional intake of vitamin D, or vitamin D, (40) that would prevent rickets in normal subjects; hence the term pseudodeficiency preferred by some investigators (34). Persistent hypocalcemia appearing soon after birth is accompanied by an excess of circulating parathyroid hormone (I) which in turn is associated with hyperphosphaturia and hyperaminoaciduria (1, 37). Elevated serum alkaline phosphatase activity, severe rachitic bone lesions, and enamel hypoplasia affecting teeth that form postnatally complete the clinical syndrome ( I , l I, 14, 18, 34, 36) . Maintenance treatment with vitamin D, only at levels about 100 times the normal requirement fully reverses the manifestations of deficiency hence the term vitamin D dependency (18, 36) .
The origin of the disturbed physiology in ARVDD lies in a selective disturbance of calcium absorption by intestine (18) . A defect either in the biosynthesis of the active hormone form of vitamin D or in the ability of target organ(s) to respond to vitamin D hormone has been proposed (36) to explain the dependency on vitamin D,, D,, or 25-OH-D, of patients with ARVDD. ARVDD patients respond to microgram doses of chemically synthesized la,25-dihydroxycholecalciferol (Ia,25-(OH),-D,) (12) . This finding has been corroborated by several investigators (3). It is surmised that a missing form of vitamin D hormone had been supplied and that ARVDD is likely to be an inborn error of vitamin D hormone biosynthesis, probably at the I-hydroxylation step (12) ; this hypothesis is in keeping with the autosomal recessive inheritance of the disease.
Treatment of ARVDD with a "surrogate" vitamin D hormone, such as la-hydroxycholecalciferol (la-OH-D,) (22, 24) , would be advantageous. Crystalline la-OH-D, is more easily synthesized than la,25-(OH),-D,, and the former can be effectively administered by mouth. Moreover, ARVDD is an experiment of nature which provides an admirable opportunity to observe the effect of la-OH-D, in man. The present report reveals the therapeutic value of crystalline la-OH-D, in ARVDD and its preference over a similar synthetic analog of vitamin D, namely dihydrotachysterol (DHTz).
